Trials / Completed
CompletedNCT02578953
Bioequivalence Study of Dutasteride Capsules in Healthy Japanese Male Subjects
Bioequivalence Study of Dutasteride Capsules-An Evaluation of the Bioequivalence of Dutasteride Capsule Manufactured at GSK Compared to Dutasteride Capsule Manufactured at Catalent in Healthy Japanese Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Male
- Age
- 20 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
This will be a single center, open-label, single dose, randomized and 2-way crossover study in healthy Japanese male subjects under fasting conditions. The study will be conducted to determine the bioequivalence between dutasteride capsules manufactured at GSK (test product) and dutasteride capsule manufactured at Catalent (reference product) in healthy Japanese male subjects. Subjects will have a screening visit within 30 days prior to the first dose of study treatment, two treatment periods separated by 28-days washout period, a re-visit 10-14 days after the second dose for the first follow-up and a second follow up via telephone 50-54 days after the second dose. The total duration of the study will be approximately 15 weeks from screening to the second follow up.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dutasteride-Test product | Dutasteride Capsules are oblong, opaque, dull-yellow, gelatin capsules. The capsules contain 0.5 mg dutasteride for oral administration. The capsules also contain Butylated Hydroxytoluene, Mono-di-glycerides of Caprylic/Capric Acid (MDC), Gelatin, Concentrated Glycerin, Titanium Dioxide, Iron Oxide Yellow as ingredients. This product will be manufactured by GSK, Poznan. |
| DRUG | Dutasteride-Reference product | Dutasteride Capsules are oblong, opaque, dull-yellow, gelatin capsules. The capsules contain 0.5 mg dutasteride for oral administration. The capsules also contain Butylated Hydroxytoluene, Mono-di-glycerides of Caprylic/Capric Acid (MDC), Gelatin, Glycerin, Concentrated Glycerin, Titanium Dioxide, Iron Oxide Yellow as ingredients. This product will be manufactured by Catalent, Beinheim. |
Timeline
- Start date
- 2015-09-09
- Primary completion
- 2015-12-15
- Completion
- 2015-12-15
- First posted
- 2015-10-19
- Last updated
- 2018-06-19
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02578953. Inclusion in this directory is not an endorsement.